Corganics®

A pharmacy-grade idea, wearing scrubs

Walk into an orthopedic clinic in Texas and ask about CBD. A few years ago you would have gotten a shrug. Today, increasingly, you get a small white bottle with a familiar dot-pattern logo and a recommendation that came from your provider, not an influencer.

That bottle is Corganics. It is a Dallas life-sciences company, roughly nineteen people, that makes broad-spectrum, THC-free CBD softgels, drops, and cream - and then deliberately keeps them off the open market. You cannot buy Corganics at a dispensary or in a checkout-line display. You buy it because a healthcare professional handed it to you. That single constraint is the whole company.

It is a strange thing to build a brand around what you refuse to sell to. Corganics did it on purpose.

Two pharma executives, one stubborn premise

Chad Collins and Reggie Gatewood did not come from the cannabis world. They came from pharmaceuticals, where supply chains are documented, batches are tested, and "trust me" is not a regulatory strategy. In January 2020 they founded the company that would become Corganics - originally under the name MD Farma - on a premise that sounds obvious until you notice nobody was doing it: treat CBD like a clinical product and sell it the way clinical products are sold.

That meant doing the unglamorous work. Manufacturing in cGMP-compliant, NSF-certified facilities. Third-party testing in ISO-certified labs. Gathering IRB-approved data. Formulating for the body's endocannabinoid system rather than guessing. And, most counterintuitively, refusing the giant retail channel in favor of a slower one: licensed healthcare professionals.

The rebrand that named the strategy

In late 2021 MD Farma became Corganics, acquired a topical analgesic line called Relief, and raised a Series A. The new name was less about marketing polish and more about declaring the lane: corrective, clinical, organic-adjacent, and decidedly not recreational.

Three products, one promise: no surprises

The line is small on purpose. Each product is broad-spectrum hemp extract with no detectable THC, and each leans on the company's Advanced Lipid Technology (A.L.T.) - a formulation trick meant to improve bioavailability, so the body actually absorbs more of what is in the bottle instead of waving most of it goodbye.

Put the doctor back in the conversation

Corganics frames its mission around a piece of biology most people have never heard of: the endocannabinoid system, the network of receptors that helps regulate everything from sleep to inflammation. The company's stated goal is to bridge the gap between healthcare professionals and patients in understanding and treating it - and to reestablish clinicians as the trusted source for hemp-derived therapy.

It is, in a sense, a profoundly conservative mission dressed in a trendy molecule. Corganics is not trying to reinvent medicine. It is trying to drag a chaotic category back into the orderly habits medicine already had: test it, document it, let a professional recommend it.